Literature DB >> 26819053

Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.

Paolo Strati1, Joon H Uhm1, Timothy J Kaufmann1, Chadi Nabhan2, Sameer A Parikh1, Curtis A Hanson1, Kari G Chaffee1, Timothy G Call1, Tait D Shanafelt3.   

Abstract

Abroad array of conditions can lead to neurological symptoms in chronic lymphocytic leukemia patients and distinguishing between clinically significant involvement of the central nervous system by chronic lymphocytic leukemia and symptoms due to other etiologies can be challenging. Between January 1999 and November 2014, 172 (4%) of the 4174 patients with chronic lymphocytic leukemia followed at our center had a magnetic resonance imaging of the central nervous system and/or a lumbar puncture to evaluate neurological symptoms. After comprehensive evaluation, the etiology of neurological symptoms was: central nervous system chronic lymphocytic leukemia in 18 patients (10% evaluated by imaging and/or lumbar puncture, 0.4% overall cohort); central nervous system Richter Syndrome in 15 (9% evaluated, 0.3% overall); infection in 40 (23% evaluated, 1% overall); autoimmune/inflammatory conditions in 28 (16% evaluated, 0.7% overall); other cancer in 8 (5% evaluated, 0.2% overall); and another etiology in 63 (37% evaluated, 1.5% overall). Although the sensitivity of cerebrospinal fluid analysis to detect central nervous system disease was 89%, the specificity was only 42% due to the frequent presence of leukemic cells in the cerebrospinal fluid in other conditions. No parameter on cerebrospinal fluid analysis (e.g. total nucleated cells, total lymphocyte count, chronic lymphocytic leukemia cell percentage) were able to offer a reliable discrimination between patients whose neurological symptoms were due to clinically significant central nervous system involvement by chronic lymphocytic leukemia and another etiology. Median overall survival among patients with clinically significant central nervous system chronic lymphocytic leukemia and Richter syndrome was 12 and 11 months, respectively. In conclusion, clinically significant central nervous system involvement by chronic lymphocytic leukemia is a rare condition, and neurological symptoms in patients with chronic lymphocytic leukemia are due to other etiologies in approximately 80% of cases. Analysis of the cerebrospinal fluid has high sensitivity but limited specificity to distinguish clinically significant chronic lymphocytic leukemia involvement from other etiologies. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26819053      PMCID: PMC5004406          DOI: 10.3324/haematol.2015.136556

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  38 in total

1.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Authors:  Sophie Bernard; Lauriane Goldwirt; Sandy Amorim; Pauline Brice; Josette Brière; Eric de Kerviler; Samia Mourah; Hélène Sauvageon; Catherine Thieblemont
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

Review 2.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  Leptomeningeal metastases: MR evaluation.

Authors:  D M Yousem; P M Patrone; R I Grossman
Journal:  J Comput Assist Tomogr       Date:  1990 Mar-Apr       Impact factor: 1.826

4.  Letter: Leukaemia of the central nervous system.

Authors:  E Reske-Nielsen; J H Petersen; H Sogaard; K B Jensen
Journal:  Lancet       Date:  1974-02-09       Impact factor: 79.321

5.  CNS involvement in leukaemia. An autopsy study of 100 consecutive patients.

Authors:  M Bojsen-Møller; J L Nielsen
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1983-07

Review 6.  Infection and immunity in chronic lymphocytic leukemia.

Authors:  S Tsiodras; G Samonis; M J Keating; D P Kontoyiannis
Journal:  Mayo Clin Proc       Date:  2000-10       Impact factor: 7.616

7.  Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.

Authors:  Stefan Knop; Ulrich Herrlinger; Ulrike Ernemann; Lothar Kanz; Holger Hebart
Journal:  Leuk Lymphoma       Date:  2005-11

8.  Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.

Authors:  L Fischer; P Martus; M Weller; H A Klasen; B Rohden; A Röth; B Storek; M Hummel; T Nägele; E Thiel; A Korfel
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

9.  Primary central nervous system lymphoma as a variant of Richter's syndrome in two patients with chronic lymphocytic leukemia.

Authors:  B P O'Neill; T M Habermann; P M Banks; J R O'Fallon; J D Earle
Journal:  Cancer       Date:  1989-09-15       Impact factor: 6.860

10.  Central nervous system expression of a monoclonal paraprotein in a chronic lymphocytic leukemia patient.

Authors:  P Ruiz; M Moezzi; W Chamizo; P Ganjei; C C Whitcomb; L C Rey
Journal:  Acta Haematol       Date:  1992       Impact factor: 2.195

View more
  21 in total

1.  Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.

Authors:  Gianluigi Reda; Ramona Cassin; Gabriela Dovrtelova; Cristina Matteo; Juri Giannotta; Maurizio D'Incalci; Agostino Cortelezzi; Massimo Zucchetti
Journal:  Haematologica       Date:  2019-02-14       Impact factor: 9.941

2.  Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients.

Authors:  Chiara Briani; Andrea Visentin; Alessandro Salvalaggio; Silvia Imbergamo; Francesco Piazza; Mario Cacciavillani; Marta Campagnolo; Federica Frezzato; Gianpietro Semenzato; Livio Trentin
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

3.  Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.

Authors:  Alipi V Naydenov; Lynne P Taylor
Journal:  Oncologist       Date:  2019-03-06

Review 4.  Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy.

Authors:  Yuanquan Yang; Jingxin Qiu; Abigail Snyder-Keller; Yongping Wu; Shufeng Sun; Haixin Sui; Amy B Dean; Laura Kramer; Francisco Hernandez-Ilizaliturri
Journal:  Am J Hematol       Date:  2018-01-25       Impact factor: 10.047

5.  Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22.

Authors:  F Arruga; B Gizdic; C Bologna; S Cignetto; R Buonincontri; S Serra; T Vaisitti; K Gizzi; N Vitale; G Garaffo; E Mereu; F Diop; F Neri; D Incarnato; M Coscia; J Allan; R Piva; S Oliviero; R R Furman; D Rossi; G Gaidano; S Deaglio
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

6.  Chronic Lymphocytic Leukemia Resulting in Hemorrhagic Brain Masses After Sepsis.

Authors:  Aaron M Gusdon; Sung-Min Cho; Yunis Mayasi; Rachna Malani; Hans A Püttgen; Amy Duffield; Javier Bolaños-Meade; Michael Lim
Journal:  Neurohospitalist       Date:  2019-07-02

7.  Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement.

Authors:  Nishika Karbhari; Hugo Lara-Martinez; John M Hill
Journal:  Case Rep Oncol       Date:  2022-03-30

8.  Chronic lymphocytic leukemia with clinical debut as neurological involvement: a rare phenomenon and the need for better predictive markers.

Authors:  Cristhiam M Rojas-Hernandez; Jacklyn Nemunaitis; Kristopher D Marjon; Daniel Bustamante; Qian-Yun Zhang; Jennifer M Gillette
Journal:  BMC Hematol       Date:  2017-02-02

9.  Brain biopsy in the diagnosis of leptomeningeal involvement in stage I chronic lymphocytic leukemia.

Authors:  Eva Cervilla Muñoz; Pablo Demelo Rodríguez; Alejandra García García; Javier Menarguez Palanca; Jorge Del Toro Cervera
Journal:  Clin Case Rep       Date:  2017-10-06

10.  Unusual Relapse of Chronic Lymphocytic Leukemia After Remission.

Authors:  Wajeeha Rizvi; Quoc Truong
Journal:  Cureus       Date:  2018-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.